Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Withdrawn
Onstryv safinamide Parkinson's disease Do not reimburse Complete
Onureg azacitidine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab classical Hodgkin Lymphoma (cHL) after failure of ASCT Reimburse with clinical criteria and/or conditions Complete
Opdivo Nivolumab Metastatic Hepatocellular Carcinoma (HCC) Do not reimburse Complete
Opdivo Nivolumab Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Esophageal or gastroesophageal junction cancer Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Gastroesophageal junction or esophageal adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Urothelial carcinoma Reimburse with clinical criteria and/or conditions Complete
Opdivo nivolumab Resectable Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete